ArticleTrials2022

Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.

Shaukat Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.